Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 5Mucositis 2Febrile Neutropenia 2Unspecified Adult Solid Tumor, Protocol Specific 1Smoldering Multiple Myeloma 1Recurrence 1Rectal Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Hematologic Neoplasms 1Cytokine Release Syndrome 1Cryopyrin-Associated Periodic Syndromes 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT01624766 2021-02-25

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

M.D. Anderson Cancer Center

Phase 1 Completed
57 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡